case_images: PMC8323493_01
case_images: Cell fate propensities were obtained from the in vivo Drosophila Patient Model using Bangi et al.'s study. Cell fate propensities under (A) control, mutated, and therapy (Trametinib), (B) control, mutated, and therapy (Zoledronate), (C) control, mutated, and therapy (Trametinib + Zoledronate), (D) control, mutated, and therapy (Trametinib, Zoledronate, and Trametinib + Zoledronate).
case_images: fonc-11-692592-g006.jpg
case_images: PMC8323493_01_fonc-11-692592-g006.jpg
case_images: f6
case_images: Next, with the administration of trametinib, an inhibitor of MEK kinase (mitogen-activated protein kinase kinase), used to treat patients with Kras mutation, the propensities for proliferation decreased to 0.000, whereas apoptosis increased to 0.386 ( Figure 6A ). With the administration of zoledronate, the cell fate propensities came out to be 0.130 for proliferation and 0.324 in the case of apoptosis ( Figure 6B ). Next, with the induction of zoledronate in combination with trametinib, a decrease in proliferation to 0.000 and an increase in apoptosis to 0.386 was observed ( Figure 6C ). Interestingly, augmentation of therapy with in tandem administration of trametinib, zoledronate, and trametinib with zoledronate showed proliferation to decrease to 0.000 and apoptosis to increase to 0.400 propensities ( Figure 6D ).